序号	中文	英文	操作
15431	将在获得更多数据时对这些建议做出调整。	Recommendations will be adjusted when more data become available.	查看中文全文00445 查看英文全文00445
15432	逾百万人获得丙肝高效药物治疗	Over 1 million treated with highly effective hepatitis C medicines	查看中文全文00446 查看英文全文00446
15433	2016年10月27日 | 新闻稿 | 日内瓦	27 October 2016 | News release | GENEVA	查看中文全文00446 查看英文全文00446
15434	价格昂贵是获取药物的主要障碍	High prices–a major barrier to access	查看中文全文00446 查看英文全文00446
15435	自两年前使用具有突破性的丙肝新治愈方法以来，低收入和中等收入国家已有逾百万人得到治疗。	Over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.	查看中文全文00446 查看英文全文00446
15436	当直接作用抗病毒药物于2013年被首次批准用于丙肝治疗时，人们普遍担心其昂贵的价格会使全世界8000多万名慢性丙肝感染者望尘莫及。	When Direct Acting Antivirals (DAAs) were first approved for hepatitis C treatment in 2013, there were widespread fears that their high price would put them out of reach for the more than 80 million people with chronic hepatitis C infections worldwide.	查看中文全文00446 查看英文全文00446
15437	新型药物的治愈率达到95%以上，与以往治疗方式相比副作用则更少，且能够在三个月内使该病得到完全治愈。	The new medicines have a cure rate of over 95%, fewer side effects than previously available therapies, and can completely cure the disease within three months.	查看中文全文00446 查看英文全文00446
15438	然而大约8.5万美元这一最初估计价格即使在高收入国家也使人难以承受。	But at an initial estimated price of some US$85 000 they were unaffordable even in high-income countries.	查看中文全文00446 查看英文全文00446
15439	国家情况显示可以实现丙肝治疗	Countries show hepatitis C treatment is achievable	查看中文全文00446 查看英文全文00446
15440	由于在世卫组织和其它合作伙伴支持下采取了一系列药物获取策略，包括阿根廷、巴西、埃及、格鲁吉亚、印度尼西亚、摩洛哥、尼日利亚、巴基斯坦、菲律宾、罗马尼亚、卢旺达、泰国和乌克兰在内的多个低收入和中等收入国家开始使存有需求的病人真正得到这一药物。	Thanks to a series of access strategies supported by the World Health Organization (WHO) and other partners, a range of low- and middle-income countries, including Argentina, Brazil, Egypt, Georgia, Indonesia, Morocco, Nigeria, Pakistan, Philippines, Romania, Rwanda, Thailand and Ukraine – are beginning to succeed in getting drugs to people who need them.	查看中文全文00446 查看英文全文00446